AAQ1.F aap Implantate AG
- Market cap
- EUR 20.0M
- P/E
- -
- P/B
- 2.54x
- ROE
- -29.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is AAQ1.F undervalued?
Graham numberThe Graham number of aap Implantate AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
aap Implantate AG fundamental analysis
No fundamental analysis for aap Implantate AG yet.
aap Implantate AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About aap Implantate AG
aap Implantate AG develops, manufactures, and markets traumatology products for orthopedics in Germany and internationally. The company offers LOQTEQ, an anatomical plating system for the treatment of ankle, straight plates, knee, elbow, wrist, and shoulder. It also provides cannulated screws, as well as offers antibacterial silver coating technology and our magnesium-based implants. The company sells its products directly to hospitals, purchasing groups, and hospital groups…
Full company profileaap Implantate AG financial statements
aap Implantate AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 10.5M | 10.9M | 10.8M | 11.7M | 9.33M | 12.2M | 11.5M | 11.5M | 12.2M | 12.5M |
| Gross Profit | 8.79M | 9.80M | 10.3M | 10.6M | 7.96M | 10.9M | 10.6M | 9.98M | 10.7M | 11.1M |
| Operating Income | -9.90M | -8.04M | -8.17M | -18.3M | -7.63M | -2.69M | -3.39M | -7.05M | -2.72M | -2.55M |
| EBITDA | - | -7.47M | -5.89M | -6.44M | -5.40M | -520K | -1.57M | -3.28M | -1.19M | -666K |
| Net Income | 14.6M | -9.27M | -7.67M | -19.4M | -8.79M | -2.70M | -2.56M | -7.96M | -3.63M | -2.59M |
| EPS | - | -3.18 | -2.62 | -6.06 | -0.27 | -0.54 | -0.39 | -0.89 | -0.30 | -0.19 |
| Balance Sheet | ||||||||||
| Total Assets | 63.9M | 50.5M | 42.2M | 26.3M | 19.7M | 23.0M | 20.2M | 17.3M | 15.8M | 13.8M |
| Total Liabilities | 9.08M | 7.91M | 7.30M | 7.42M | 9.41M | 10.2M | 7.40M | 9.18M | 5.38M | 5.06M |
| Shareholders' Equity | 54.8M | 42.6M | 34.9M | 18.9M | 10.3M | 12.8M | 12.8M | 8.10M | 10.5M | 8.70M |
| Cash & Short-term Investments | 23.8M | 13.3M | 4.26M | 2.93M | 885K | 2.11M | 236K | 1.28M | 2.07M | 661K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -7.20M | -5.43M | -5.92M | -5.77M | -3.68M | -2.47M | -1.89M | -2.92M | -1.12M | -1.43M |
| Capital Expenditure | 810K | 810K | 810K | 407K | 334K | 329K | 485K | 406K | 330K | 725K |
| Free Cash Flow | - | -6.79M | -8.08M | -7.46M | -4.09M | -2.99M | -2.38M | -3.32M | -1.45M | -2.16M |
| Ratios | ||||||||||
| ROE | 26.7% | -21.8% | -22.0% | -103.0% | -85.4% | -21.1% | -20.0% | -98.3% | -34.7% | -29.7% |
| ROA | 22.9% | -18.4% | -18.2% | -73.9% | -44.6% | -11.8% | -12.7% | -46.1% | -22.9% | -18.8% |
| Net Profit Margin | 139.5% | -85.0% | -71.1% | -165.6% | -94.3% | -22.2% | -22.3% | -69.4% | -29.7% | -20.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
aap Implantate AG dividends
aap Implantate AG has not paid dividends in the last 10 fiscal years.
Last stock split: 1:10 on Oct 29, 2020.
Who owns aap Implantate AG
- Insiders 61.81%
- Institutions 23.06%
- Public & others 15.13%
- Shares outstanding 14.8M
- Free float 5.90M
aap Implantate AG company profile
- Company name
- aap Implantate AG
- Ticker
- AAQ1.F
- ISIN
- DE000A3H2101
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 105
- Fiscal year end
- December
- Address
- Lorenzweg 5, Berlin, Germany, 12099
- Phone
- 49 30 75019 0
- Website
- aap.de
About aap Implantate AG
aap Implantate AG develops, manufactures, and markets traumatology products for orthopedics in Germany and internationally. The company offers LOQTEQ, an anatomical plating system for the treatment of ankle, straight plates, knee, elbow, wrist, and shoulder. It also provides cannulated screws, as well as offers antibacterial silver coating technology and our magnesium-based implants. The company sells its products directly to hospitals, purchasing groups, and hospital groups through a network of distributors. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.
aap Implantate AG management
3- Mr. Rubino Di GirolamoChairman of the Management Board & CEO · born 1962
- Ms. Nicole KasselCFO & Member of Management Board
- Mr. Cornelius FinkCOO & Member of Management Board